A Management Shake-Up At Pfizer Raises Questions
Executive Summary
2011 is likely to be a defining year for Pfizer and the Big Pharma has hit the ground running. In early December, the board of directors announced a management shake-up, as CEO Jeff Kindler resigned unexpectedly and the board simultaneously elected veteran Pfizer executive Ian Read to replace him. In the ensuing weeks, the board also named a new non-executive chairman, George Lorch, former chairman and CEO of the diversified conglomerate Armstrong Holdings. In addition, it consolidated leadership of several business units and appointed some of those leaders to its executive committee.
You may also be interested in...
Freed From Pfizer, Capsugel May Find More Market Opportunities
Deal heightens attention Pfizer is attracting from the investment community, already anticipating divestments outside the firm's innovative core pharma business.
Freed From Pfizer, Capsugel May Find More Market Opportunities
Deal heightens attention Pfizer is attracting from the investment community, already anticipating divestments outside the firm's innovative core pharma business.
Reading Into Pfizer's Changes: First Steps For New CEO
Pfizer Inc.'s new CEO Ian Read came out of the gates strong during the company's year-end financial presentation Feb. 1, with news that investors greeted warmly: additional, unexpected cuts to R&D and further R&D reorganization, a $5 billion share buyback program, and assurance that all options are on the table when it comes to Pfizer's diversified portfolio of businesses.